0:00
welcome back to health awareness YouTube
0:01
channel in this video we share more
0:04
light on the latest move in getting cure
0:05
for the HIV virus here are the key
0:08
highlights Gilead's twice yearly
0:10
medicine to prevent Ivy succeeded in a
0:13
phase three trial none of the roughly
0:16
2,000 women in the trial who received
0:18
the Lin cap ofir shot contracted Hive
0:21
gilad needs to replicate the results in
0:23
another phase three trial before seeking
0:25
FDA approval the company expects to
0:27
share more data later this year or early
0:30
next year if the results are positive
0:33
Lena kavir for prep could reach the
0:35
market as soon as late
0:37
2025 now before we get into more details
0:40
don't forget to hit the Subscribe button
0:42
to stay updated on the latest news on
0:44
HIV prevention and cure Gilead's
0:47
experimental twice yearly High
0:49
prevention medication Lena kavir
0:52
demonstrated 100 Effectiveness in a late
0:54
stage trial the company announced
0:57
Thursday in an interim analysis none of
1:00
the approximately 2,000 women in the
1:02
trial who received the Len capir
1:04
injection contracted hiie this led the
1:07
independent data monitoring committee to
1:09
recommend that gilad unblind the phase 3
1:11
trial and offer treatment to all
1:14
participants those who had not received
1:16
the shot were given standard daily pills
1:19
these promising results bring Gilead
1:21
closer to introducing a new form of
1:23
pre-exposure prophylaxis prep and
1:26
expanding its high ve business following
1:28
the Announcement J IAD shares Rose by
1:31
about seven what the world needs is
1:34
people to have more prep options so they
1:36
can make the choice of the option that's
1:38
going to work best for them said Jared
1:40
Bon gilad's vice president of clinical
1:44
HIV before seeking approval from the
1:47
Food and Drug Administration Gilead will
1:49
need to replicate these results the
1:51
company plans to release data later this
1:54
year or early next year from an ongoing
1:56
phase three study involving men who have
1:58
sex with men positive results could see
2:01
Lop air for prep brought to Market as
2:05
2025 more than a decade ago gilad's
2:07
trouva became the first approved prep
2:09
for individuals at high risk of HIV
2:12
while daily pills dominate the market
2:14
drug makers are now developing longer
2:17
injections prep reduces the risk of
2:19
acquiring HIV from sex by 99 and from
2:22
injected drug use by 74 when taken
2:25
correctly however only about 1third of
2:28
eligible individuals in the US use prep
2:31
according to the Centers for Disease
2:32
Control and prevention Health policy
2:35
makers and Advocates hope longer acting
2:37
options will reach individuals who
2:39
cannot or prefer not to take a daily
2:41
pill thus better preventing the spread
2:43
of hi ve which caused about 1 million
2:45
new infections globally in
2:48
2022 it's really important to have more
2:50
options than daily pills because the
2:52
orals aren't going to get us to the end
2:54
of the epidemic said Bruce Richmond
2:56
founding executive director of the
2:58
nonprofit prevention access campaign
2:59
aign we need to make sure that people
3:01
have options to fit with their
3:03
Lifestyles the FDA approved the first
3:06
injectable prep a prude in 2021 this
3:09
drug administered every 2 months is used
3:12
by about 11,000 people according to its
3:16
veve Tim Oliver a 28-year-old Public
3:19
Health worker in New York said he
3:21
doesn't mind going to the doctor for his
3:23
Aude shots but noted that some friends
3:26
prefer daily pills over injections a
3:28
longer acting option could appeal more
3:30
to patients RBC Capital markets analyst
3:34
Brian Abrahams anticipates that gilad's
3:36
shot will significantly increase
3:38
interest in preventive IV medicine
3:40
predicting Peak sales of nearly $2
3:42
billion gilad's newer prep pill Desy
3:46
generated around $2 billion in Revenue
3:48
last year activists have urged gilad to
3:52
ensure access to Len capir in low in
3:55
Middle inome countries the company has
3:57
faced long-standing criticism over the
3:59
price of it HIV medicines with Desy
4:02
costing $26,000 annually a its statement
4:06
on the Len cap of trial results gilad
4:08
said it plans to update how it will
4:10
address access in countries with high
4:13
HIV incidence rates thanks for watching
4:16
this episode for more HIV news update
4:18
don't forget to hit the Subscribe button
4:21
share with your friends and family and
4:22
turn on the notification Bell see you in
